InMode Ltd. (NASDAQ:INMD) Shares Bought by Doma Perpetual Capital Management LLC

Doma Perpetual Capital Management LLC boosted its stake in InMode Ltd. (NASDAQ:INMD - Free Report) by 210.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,011,240 shares of the healthcare company's stock after acquiring an additional 1,363,841 shares during the period. InMode comprises approximately 17.0% of Doma Perpetual Capital Management LLC's portfolio, making the stock its 2nd largest position. Doma Perpetual Capital Management LLC owned approximately 2.39% of InMode worth $36,685,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of INMD. Lombard Odier Asset Management Europe Ltd acquired a new stake in shares of InMode during the second quarter worth about $4,104,000. Sei Investments Co. grew its holdings in InMode by 8.5% during the second quarter. Sei Investments Co. now owns 144,181 shares of the healthcare company's stock worth $2,630,000 after acquiring an additional 11,342 shares during the period. Herr Investment Group LLC purchased a new position in shares of InMode in the 2nd quarter valued at about $274,000. Hsbc Holdings PLC lifted its stake in shares of InMode by 129.7% in the second quarter. Hsbc Holdings PLC now owns 90,280 shares of the healthcare company's stock valued at $1,659,000 after purchasing an additional 50,974 shares during the period. Finally, Renaissance Technologies LLC lifted its position in shares of InMode by 11.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,068,396 shares of the healthcare company's stock valued at $37,728,000 after acquiring an additional 214,200 shares during the period. Institutional investors and hedge funds own 68.04% of the company's stock.

InMode Stock Performance

InMode stock traded up $0.75 during trading on Thursday, reaching $17.19. 869,176 shares of the company's stock were exchanged, compared to its average volume of 1,360,737. The company's 50-day moving average is $16.66 and its two-hundred day moving average is $17.99. InMode Ltd. has a 52-week low of $15.39 and a 52-week high of $33.62. The firm has a market cap of $1.44 billion, a price-to-earnings ratio of 8.12 and a beta of 2.17.

InMode (NASDAQ:INMD - Get Free Report) last posted its earnings results on Thursday, August 1st. The healthcare company reported $0.34 EPS for the quarter, missing analysts' consensus estimates of $0.38 by ($0.04). InMode had a return on equity of 21.00% and a net margin of 35.81%. The firm had revenue of $102.60 million for the quarter, compared to analyst estimates of $104.81 million. During the same period in the previous year, the firm posted $0.65 earnings per share. The company's revenue for the quarter was down 24.6% on a year-over-year basis. Analysts anticipate that InMode Ltd. will post 1.63 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on INMD. Jefferies Financial Group cut shares of InMode from a "buy" rating to a "hold" rating and lowered their price objective for the company from $21.00 to $19.00 in a research note on Tuesday, July 23rd. Canaccord Genuity Group lowered their target price on shares of InMode from $21.00 to $16.00 and set a "hold" rating for the company in a research note on Friday, July 12th. Needham & Company LLC reissued a "hold" rating on shares of InMode in a research note on Thursday, July 11th. Finally, Barclays decreased their price target on shares of InMode from $33.00 to $29.00 and set an "overweight" rating on the stock in a report on Monday, July 15th. Five analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $22.40.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.